Artificial intelligence was impossible to miss at HLTH Europe in Amsterdam. It appeared on the main stage, throughout the agenda, across the exhibition floor, and dominated conversations among providers, researchers, investors, entrepreneurs, and policymakers. Much of the public discussion around AI continues to focus on familiar names such as OpenAI, Gemini, Copilot and Perplexity. Their influence is undeniable, helping introduce artificial intelligence to mainstream audiences and accelerating adoption across industries.

The Exhibition Floor as a Market Signal

However, after several days walking the exhibition floor and listening to discussions across multiple stages, another story emerged. The most interesting development at HLTH Europe was not the continued rise of AI. It was the growing number of companies applying artificial intelligence to solve very specific challenges faced by researchers, physicians, health systems and patients.

What appears on the stages and exhibition floor at HLTH often reflects where the market sees opportunity. Conferences do not create trends. They reveal them. HLTH Europe brought together more than 400 speakers, some 350 sponsors and approximately 5,000 participants from across the global health ecosystem. Artificial intelligence was not simply one topic among many. The conference featured a dedicated AI @ HLTH Zone, AI-focused exhibitors and numerous sessions exploring implementation, governance, clinical applications and operational adoption.

The prominence of AI across both the agenda and exhibition hall was revealing. Conference organizers dedicate space and programming to topics that matter to attendees, investors and sponsors. The visibility of AI at HLTH Europe suggested that health-specific applications of artificial intelligence have moved beyond emerging interest and are now a significant market focus.

That shift matters because health has always demanded more than technological capability. New tools must operate within environments where privacy, safety, accountability and trust are essential. Researchers are looking for ways to accelerate discovery. Physicians want to reduce administrative burdens that consume valuable time. Health systems seek efficiencies that improve operations without compromising quality. Increasingly, innovators are designing AI solutions around those specific needs.

That reality helps explain why many of the most compelling AI companies at HLTH Europe are building solutions specifically for health rather than adapting tools designed for other industries.

As Sophie Taylor-Roberts, managing partner and FINN Partners UK Health Group Lead, shared: “A mistake in healthcare carries a human cost: it can literally mean life or death. That’s why healthcare needs bespoke AI models, tools and solutions that allow for diverse patient populations, differing clinical guidelines, funding and regulatory structures.”

She added, “As with all aspects of health, one size doesn’t fit all. AI must be treated like a highly specialized medical instrument, built to respect national sovereignty, multilingual patient care, and absolute data privacy.”

Health-Specific AI Moves from Possibility to Practice

The trend was visible throughout the exhibition hall, where companies focused on clinical research, physician workflow, diagnostics, patient engagement, digital safety and operational efficiency demonstrated how specialized AI is rapidly becoming a category of its own.

The trend was visible throughout the exhibition hall, where companies focused on clinical research, physician workflow, diagnostics, patient engagement, digital safety and operational efficiency demonstrated how specialized AI is rapidly becoming a category of its own. Their growth reflects a broader shift occurring across the health sector as organizations seek tools designed for specific scientific, clinical and operational challenges.

Gabriele Ricci, Chief Data & Technology Officer at Takeda, captured that evolution when discussing AI’s growing role across the research and development continuum. “AI is transforming the future of healthcare by accelerating every stage of the R&D value chain through purpose-built capabilities tailored to specific scientific and clinical challenges,” he said.

His emphasis on purpose-built capabilities mirrors what was visible throughout HLTH Europe. The conversation is no longer centered exclusively on artificial intelligence as a technology platform. Increasingly, attention is turning toward how specialized applications can address distinct needs across research, clinical care and health operations.

Among the companies reflecting this shift was Briya, whose AI-powered platform helps researchers interact with complex data through conversational interfaces. Rather than requiring users to navigate multiple databases, coding environments and analytical tools, the platform seeks to simplify the path from question to insight.

David Lazerson, Briya’s co-founder and chief executive officer, believes many organizations misunderstand where the greatest challenge in AI adoption resides.

“Many people assume AI adoption is about choosing the right model,” he said. “In reality, the model is only a small part of the solution. The hard part is everything around it: security, governance, data harmonization, domain expertise, and the methodology required to produce trustworthy outcomes.”

His observation reflects a reality becoming increasingly evident throughout the health sector. Access to powerful AI models is expanding rapidly, shifting competitive advantage toward organizations that can generate reliable outcomes within specific health environments. That reality helps explain the growing number of exhibitors focused on narrowly defined use cases rather than general-purpose AI.

A similar perspective emerged from conversations with Keith Grimes, MD, Chief Innovation Officer at Curistica. A physician who spent 24 years in primary care, Grimes approaches artificial intelligence through the lens of risk management, governance and patient safety.

“Physicians have always governed risk,” he explained. “We do it instinctively for doctors, drugs and devices. Digital is just the fourth D, and the discipline is much the same, but it is the one we were never trained for, so the commitment to ‘do no harm’ runs ahead of the know-how.”

His comments address one of the most significant challenges facing health organizations today. Many leaders recognize the promise of AI, yet remain uncertain about implementation, oversight and accountability, particularly in smaller physician practices and community-based care settings.

Dr. Grimes emphasizes that smaller organizations should not view those limitations as barriers.

“Small practices are the cornerstone of primary care, but they cannot out-resource a hospital trust, and it does not need to,” he said. “Good governance scales down, and the same standards that protect a large organization can be borrowed rather than rebuilt.”

“We give whoever is responsible for AI and digital safety both the platform and the people,” Dr. Grimes said. “Power tools that guide them, whatever their experience, with clinical safety experts behind the software.”

Taken together, the perspectives of Dr. Grimes and Lazerson point to the emergence of a new category of innovation. The most promising health AI companies are not focused exclusively on algorithms. They are creating environments that combine technology, expertise and governance to solve specific high-friction problems.

The Future Belongs to Reliable Outcomes

For smaller organizations, this evolution may prove particularly significant. Historically, adopting advanced technology often required substantial investment, specialized technical talent and complex integration efforts. Many health organizations lacked the resources to pursue those initiatives.

Lazerson believes that model is changing. “That’s why we’re seeing the emergence of a new layer of domain-specific AI,” he said. “Instead of every organization hiring AI engineers and building custom infrastructure, they can access a complete, purpose-built environment as a service.”

The implications extend far beyond research organizations. Physician practices, community health providers, home health agencies and emerging life science companies increasingly have access to capabilities that previously required significant internal resources.

“For smaller organizations in particular, it’s a no-brainer,” Lazerson added. “They can start generating value immediately without complex integrations, dedicated AI teams, or having to solve privacy, security, and compliance challenges on their own.”

Throughout HLTH Europe, companies focused on clinical research, workflow automation, diagnostics, care coordination and patient engagement demonstrated how artificial intelligence is becoming increasingly specialized. Rather than attempting to transform every aspect of health simultaneously, they are concentrating on areas where measurable value can be achieved quickly and responsibly.

That focus on practical outcomes may ultimately become the defining characteristic of the next generation of health innovation.

Dr. Grimes summarized the principle succinctly. “Safety is not a box-ticking exercise; it works when everyone knows the part they play,” he said. “The advantage is not scale, it is fit.”

Walking through HLTH Europe, I was reminded that innovation rarely advances through a single breakthrough. More often, progress emerges through focused efforts to solve meaningful problems. The companies attracting attention were helping researchers move faster, supporting clinicians facing administrative burdens and enabling organizations to adopt new capabilities with greater confidence.

Perhaps among the more important lessons from HLTH Europe. The future of AI in health will not be defined solely by the largest platforms. It will be shaped by innovators who combine technology, expertise, and specificity to deliver reliable outcomes. As Lazerson observed, “The future won’t belong to organizations with the biggest models. It will belong to those who can turn AI into reliable outcomes.”

Judging by what appeared across the stages and exhibition floor in Amsterdam, that future is taking shape.